Edmonton – TheNewswire – August 18th, 2020. Innovotech Inc. (TSXV:IOT) is pleased to report the signing of a non-dilutive earn-in acquisition agreement with Nou Life Sciences Inc. (“Nou Life”). Under the Agreement, Innovotech acquires the right, but not the obligation, to earn a 60% undivided equity interest in Nou Life in return for completing an investment of $100,000 of development expenses on Nou Life’s patented skin treatment technology over a 2-year period.
The Nou Life patent rests on the linking of alpha lipoic acid and L-carnitine into one molecule. Both Lipoic acid and Carnitine are well known antioxidants that have applications in health care, including skin products. The linking of the two molecules has been indicated by Nou Life to increase the beneficial properties of the separate molecules by improving their transdermal penetration, which is necessary in order to perform subdermal antioxidant activity toward a healthier skin. The objective of the earn-in Agreement is to confirm performance of the linked molecules toward a more effective antioxidant in skin care applications.
Innovotech’s research and testing of the linked molecules will seek to confirm that the linked molecules improve function in skin treatment sufficiently to encourage their use in nutraceutical and cosmetic applications. At the same time, Innovotech will investigate the indicated extent of the molecule’s skin penetration in anticipation of a positive effect on nerve cell reinvigoration for treatment of neuropathy.
“Based on the positive feedback in the literature around lipoic acid and L-carnitine separately, having the two compounds linked adds considerable potential. I look forward to starting work on this project.” said Dr. Amin Omar, Chief Operating Officer of Innovotech.
About Nou Life Sciences Inc.
Nou Life was conceived as a nutraceutical development company and owns the patent for the linking of Lipoic Acid and Carnitine.
About Innovotech Inc.
Innovotech is a Canadian biotechnology company owning proprietary intellectual property, conducting contract research, and owning and providing proprietary devices for testing in multiple applications in microbiology.
Director & CFO
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of materials in this news release.
Copyright (c) 2020 TheNewswire – All rights reserved.